CD19 and diffuse large B-cell lymphoma: Very recently, a retrospective report has analyzed the DESCAR-T registry, which collects data of patients treated with the approved anti-CD19 CAR-T regimens in a real life setting during the last four years, with the aim to obtain evidence on DLBCL-type RS [145].